Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
LNC1004 developers
Bedford, Massachusetts, United States
- Ownership
- Private
- Employees
- ~800
- Development stage
- Other
01
Overview
Lantheus is a leading radiopharmaceutical company focused on developing and commercializing innovative diagnostic and therapeutic agents for oncology and cardiovascular diseases. The company is well-known for its market-leading PSMA-targeted PET imaging agent, Pylarify, and its robust pipeline of theranostic candidates. Lantheus has significantly expanded its portfolio through strategic acquisitions, including Progenics Pharmaceuticals and the licensing of late-stage radiopharmaceutical assets from POINT Biopharma. The company's development of LNC1004 (a FAP-targeted ligand) highlights its commitment to next-generation precision medicine in oncology.
- Therapeutic areas
- OncologyCardiovascularNeurology
- Modalities
- RadiopharmaceuticalSmall moleculePeptides
- Industry
- Biotech
02
Partnerships
POINT BiopharmaEli LillyRegeneronBayer
Beyond the preview
Go deeper on LNC1004 developers.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LNC1004 developers.